Ioanna Gouni-Berthold

Summary

Affiliation: University of Cologne, Dept. of Internal Medicine II
Location: Cologne, Germany
URL: http://innere2.uk-koeln.de/forschung/ag-gouni-berthold/group-members

Publications

  1. pmc Patterns and predictors of statin prescription in patients with type 2 diabetes
    Heiner K Berthold
    Charite University Medicine Berlin, Virchow Clinic Campus, Lipid Clinic at the Interdisciplinary Metabolism Center, Berlin, Germany
    Cardiovasc Diabetol 8:25. 2009
  2. doi request reprint Role of physician gender in drug therapy
    I Gouni-Berthold
    University of Cologne, Cologne, Germany
    Handb Exp Pharmacol . 2012
  3. ncbi request reprint Treatment of Cardiovascular Risk Factors in Women
    I Gouni-Berthold
    Center for Endocrinology, Diabetes and Preventive Medicine ZEDP, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    Curr Med Chem 22:3580-96. 2015
  4. doi request reprint Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine ZEDP, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany Electronic address
    Atheroscler Suppl 18:28-34. 2015
  5. doi request reprint PCSK9 antibodies: A new class of lipid-lowering drugs
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine ZEDP, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany Electronic address
    Atheroscler Suppl 18:21-7. 2015
  6. pmc PCSK9 antibodies for the treatment of hypercholesterolemia
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine ZEDP, University of Cologne, Kerpener Str 62, Cologne 50937, Germany
    Nutrients 6:5517-33. 2014
  7. ncbi request reprint Familial hypercholesterolemia: etiology, diagnosis and new treatment options
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine ZEDP, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    Curr Pharm Des 20:6220-9. 2014
  8. ncbi request reprint Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    Curr Pharm Des 20:5025-38. 2014
  9. pmc Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo
    Ioanna Gouni-Berthold
    University of Cologne, Center for Endocrinology, Diabetes and Preventive Medicine, Cologne, Germany
    PLoS ONE 8:e72858. 2013
  10. ncbi request reprint The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease
    Ioanna Gouni-Berthold
    Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Kerpener St 62, 50937 Cologne, Germany
    Curr Pharm Des 20:3705-15. 2014

Collaborators

  • Heiner K Berthold
  • Wilhelm Krone
  • Kurt P Bestehorn
  • Michael Bohm

Detail Information

Publications21

  1. pmc Patterns and predictors of statin prescription in patients with type 2 diabetes
    Heiner K Berthold
    Charite University Medicine Berlin, Virchow Clinic Campus, Lipid Clinic at the Interdisciplinary Metabolism Center, Berlin, Germany
    Cardiovasc Diabetol 8:25. 2009
    ..The aim of the study was to identify patient-related factors predicting statin prescription...
  2. doi request reprint Role of physician gender in drug therapy
    I Gouni-Berthold
    University of Cologne, Cologne, Germany
    Handb Exp Pharmacol . 2012
    ..There is until now in no area of medicine evidence to suggest that a patient will consistently receive higher quality of drug therapy by switching to a physician of a specific gender...
  3. ncbi request reprint Treatment of Cardiovascular Risk Factors in Women
    I Gouni-Berthold
    Center for Endocrinology, Diabetes and Preventive Medicine ZEDP, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    Curr Med Chem 22:3580-96. 2015
    ..These risk factors were examined in the Framingham Heart study and years later they were found in the INTERHEART study to be the 4 most important risk factors for the development of CVD. ..
  4. doi request reprint Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine ZEDP, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany Electronic address
    Atheroscler Suppl 18:28-34. 2015
    ..Objective of this narrative review is to discuss the available evidence on the safety and efficacy profile of these new drugs. ..
  5. doi request reprint PCSK9 antibodies: A new class of lipid-lowering drugs
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine ZEDP, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany Electronic address
    Atheroscler Suppl 18:21-7. 2015
    ....
  6. pmc PCSK9 antibodies for the treatment of hypercholesterolemia
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine ZEDP, University of Cologne, Kerpener Str 62, Cologne 50937, Germany
    Nutrients 6:5517-33. 2014
    ....
  7. ncbi request reprint Familial hypercholesterolemia: etiology, diagnosis and new treatment options
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine ZEDP, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    Curr Pharm Des 20:6220-9. 2014
    ..In this review, the available evidence regarding the use of these drugs in patients with FH is discussed, with particular focus on their efficacy and safety...
  8. ncbi request reprint Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    Curr Pharm Des 20:5025-38. 2014
    ..In general, a multifactorial approach is recommended to decrease cardiovascular risk in patients with the MetS...
  9. pmc Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo
    Ioanna Gouni-Berthold
    University of Cologne, Center for Endocrinology, Diabetes and Preventive Medicine, Cologne, Germany
    PLoS ONE 8:e72858. 2013
    ..The direct effects of simvastatin on irisin were also examined in primary human skeletal muscle cells (HSKMCs)...
  10. ncbi request reprint The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease
    Ioanna Gouni-Berthold
    Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Kerpener St 62, 50937 Cologne, Germany
    Curr Pharm Des 20:3705-15. 2014
    ..Finally, larger long-term studies are needed to shed more light on the effect of antidiabetic treatment on NAFLD. ..
  11. ncbi request reprint Novel approaches to the pharmacotherapy of obesity
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Kerpener St 62, 50937 Cologne, Germany
    Curr Pharm Des 19:4938-52. 2013
    ..When these options alone are not sufficient, then additional pharmacotherapy with an acceptable efficacy and safety profile could provide a useful option. ..
  12. ncbi request reprint The role of niacin in lipid-lowering treatment: are we aiming too high?
    Ioanna Gouni-Berthold
    Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Kerpener St 62, 50937 Cologne, Germany
    Curr Pharm Des 19:3094-106. 2013
    ..Based on the totality of existing evidence, niacin should in the mean time remain high in the list of lipid-modulating agents to be used in clinical practice, second after statins...
  13. doi request reprint The whey fermentation product malleable protein matrix decreases TAG concentrations in patients with the metabolic syndrome: a randomised placebo-controlled trial
    Ioanna Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Kerpener Street 62, 50937 Cologne, Germany
    Br J Nutr 107:1694-706. 2012
    ....
  14. pmc Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes
    Ioanna Gouni-Berthold
    Department of Internal Medicine II, University of Cologne, Cologne, Germany
    Diabetes Care 31:1389-91. 2008
    ..To assess whether sex differences exist in the effective control and medication treatment intensity of cardiovascular disease (CVD) risk factors...
  15. ncbi request reprint [Favorable effects of decreasing lipids in patients with diabetes mellitus]
    I Gouni-Berthold
    Klinik II und Poliklinik für Innere Medizin der Universität zu Köln, Koln, Germany
    Dtsch Med Wochenschr 131:S252-4. 2006
    ..Therefore, at present no specific recommendation for treatment of diabetics with fibrates can be made...
  16. ncbi request reprint Role of physician gender in the quality of care of cardiometabolic diseases
    I Gouni-Berthold
    Center of Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    Curr Pharm Des 17:3690-8. 2011
    ..This narrative review examines the existing evidence regarding the effects of physician gender on the quality of care provided, focusing mainly on patients with cardiometabolic diseases...
  17. ncbi request reprint Lipoprotein(a): current perspectives
    Ioanna Gouni-Berthold
    University of Cologne, Center of Endocrinology, Diabetes and Preventive Medicine, Cologne, Germany
    Curr Vasc Pharmacol 9:682-92. 2011
    ....
  18. ncbi request reprint Antisense oligonucleotides for the treatment of dyslipidemia
    I Gouni-Berthold
    Department of Internal Medicine II, University of Cologne, Cologne, Germany
    Curr Pharm Des 17:950-60. 2011
    ..Purpose of this review is to discuss the available data on the effects of various ASO used for the treatment of dyslipidemia, with the main focus on ASO against ApoB-100, the most advanced in clinical development, and on PCSK9...
  19. ncbi request reprint Vitamin D and cardiovascular disease
    Ioanna Gouni-Berthold
    Department of Internal Medicine II, University of Cologne, D 50937 Cologne, Germany
    Curr Vasc Pharmacol 7:414-22. 2009
    ..Since vitamin D deficiency is easy to screen for and treat, the confirmation of such an association could have important implications for both, patient care and health policy...
  20. ncbi request reprint Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men
    Ioanna Gouni-Berthold
    Department of Internal Medicine II, University of Cologne, Kerpener Street 62, 50937 Cologne, Germany
    Atherosclerosis 198:198-207. 2008
    ..The molecular mechanisms underlying the pronounced lipid-lowering effects of this combination have not been fully elucidated in humans...
  21. ncbi request reprint Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosis
    I Gouni-Berthold
    Department of Internal Medicine II, University of Cologne, Germany
    Curr Drug Targets Cardiovasc Haematol Disord 5:513-23. 2005
    ..Furthermore, the currently available preclinical and clinical data on PPARalpha activators as well as their future perspectives will be discussed...